Agios Pharmaceuticals, Inc. (AGIO)

Zacks Research also issued estimates ... FY2028 earnings at ($3.91) EPS. A number of other research analysts have also recently commented on AGIO. HC Wainwright dropped their price target on Agios Pharmaceuticals from $65.00 to $50.00 and set a “buy” rating for the company in a research note on Mond…

The narrative leans heavily on ... future earnings multiple. ... Have a read of the narrative in full and understand what's behind the forecasts. However, investors also need to weigh the heavy reliance on PYRUKYND and ongoing high R&D and SG&A spending, which could keep profitability under pressure…

Apr 29, 2026 [10-Q] AGIOS PHARMACEUTICALS, INC. Quarterly Earnings Report

Agios shares rose after strong earnings and Aqvesme's commercial launch. Mitapivat faces competition from Novo Nordisk's etavopivat in the treatment of sickle cell disease. Key pipeline updates and catalysts are expected in 2026, especially for tebapivat. Shares in Agios Pharmaceuticals (AGIO 1.13%)…

The previous big move we wrote about was 15 days ago when the stock gained 3.8% on the news that strong earnings from enterprise leaders ignited a massive rally across enterprise tech.